RATIONALE: An unbiased investigation of age-related gene expression changes in nasal polyps (NP) may provide new treatment targets, especially for the elderly. METHODS: Affymetrix microarrays using NP tissues and control uncinate tissues (elderly, age > _65 vs non-elderly, age 18-49; n54 each group) were performed and differentially regulated genes were analyzed with a cutoff p value <0.05 and a cutoff gene expression change >2-fold. Real-time PCR (qRT-PCR), immunohistochemistry (IHS), periodic acidSchiff (PAS) and trichrome staining were used to validate the microarray results. RESULTS: Microarray analysis identified genes regulated differentially by disease and age; 340 in NP vs controls, 446 in elderly controls vs nonelderly controls, 45 in elderly NP vs non-elderly NP, 320 in non-elderly NP vs non-elderly controls, and 190 in elderly NP vs elderly controls. qRT-PCR confirmed downregulation of PLAT (tissue-plasminogen activator-1, tPA), upregulation of SERPINE1 (plasminogen activator inhibitor-1, PAI-1) and SERPINB2 (PAI-2), and downregulation of submucosal glandrelated genes such as SCGB1D2, SCGB2A2, MUC7 and LPO (lactoperoxidase) in NP vs controls. SERPINE1 expression was significantly increased in elderly NP compared to elderly controls and PLAT expression was downregulated in non-elderly NP compared to non-elderly controls. IHC confirmed significantly reduced expression of anti-microbial proteins, MUC7 and lactoperoxidase, in NP. There was age-related reduction of serous submucosal glandular cells and relative increase of PAS-stained mucous glandular cells. Trichrome staining showed increased collagen deposition with age. CONCLUSIONS: This study demonstrates age-associated dysregulated genes in human NP, PAI-1 and tPA, which can be potential treatment targets, especially in the elderly. [EudraCT 2017-000333-31] evaluated the dose response relationship for a modified grass subcutaneous immunotherapy (SCIT) product with modified allergen tyrosine adsorbate (MATA) and monophosphoryl lipid A (MPL) adjuvants for allergic rhinoconjunctivitis (ARC) due to grass pollen. METHODS: In total 447 patients were enrolled in this randomized, double-blind, placebo-controlled, parallel group study. Patients were randomized to one of five dose regimens of 5100, 14400, 27600 and 35600 SU and placebo. The primary endpoint was the total symptom score (TSS) as measured during a conjunctival provocation test (CPT). Three dose response models were predefined: an Emax, logistic, and linear in logdose model. MCP-Mod was used to characterize a dose response relationship. RESULTS: For all three individual pre-specified dose response models a highly statistically significant dose-response (p<0.0001) was shown for the range of cumulative doses from 5100 SU to 35600 SU. The dose reaching at least 50% of the full CPT effect size over placebo (ED50) was approximately 2900 SU, in support of the currently marketed cumulative dose of 5100 SU in Europe, which is almost 2-fold higher. All doses evaluated were well tolerated. CONCLUSIONS: This study demonstrates a clear and statistically significant dose response on TSS following CPT after an ultra-short course of 6 injections with allergoid grass SCIT treatment with adjuvants MATA and MPL. Both the cumulative 27600 SU and 35600 SU doses showed a similarly optimal risk/benefit profile. Either dose may therefore be selected for further investigation in pivotal phase III studies.
] evaluated the dose response relationship for a modified grass subcutaneous immunotherapy (SCIT) product with modified allergen tyrosine adsorbate (MATA) and monophosphoryl lipid A (MPL) adjuvants for allergic rhinoconjunctivitis (ARC) due to grass pollen. METHODS: In total 447 patients were enrolled in this randomized, double-blind, placebo-controlled, parallel group study. Patients were randomized to one of five dose regimens of 5100, 14400, 27600 and 35600 SU and placebo. The primary endpoint was the total symptom score (TSS) as measured during a conjunctival provocation test (CPT). Three dose response models were predefined: an Emax, logistic, and linear in logdose model. MCP-Mod was used to characterize a dose response relationship. RESULTS: For all three individual pre-specified dose response models a highly statistically significant dose-response (p<0.0001) was shown for the range of cumulative doses from 5100 SU to 35600 SU. The dose reaching at least 50% of the full CPT effect size over placebo (ED50) was approximately 2900 SU, in support of the currently marketed cumulative dose of 5100 SU in Europe, which is almost 2-fold higher. All doses evaluated were well tolerated. CONCLUSIONS: This study demonstrates a clear and statistically significant dose response on TSS following CPT after an ultra-short course of 6 injections with allergoid grass SCIT treatment with adjuvants MATA and MPL. Both the cumulative 27600 SU and 35600 SU doses showed a similarly optimal risk/benefit profile. Either dose may therefore be selected for further investigation in pivotal phase III studies. sensitization is a common inclusion criteria in clinical trials evaluating sublingual immunotherapy (SLIT) tablets. Our aim was to evaluate the impact of pre-treatment specific IgE levels on clinical efficacy. METHODS: Data from 8 placebo-controlled phase III SLIT-tablet clinical trials (allergens: house dust mite, grass, ragweed, tree) were used in the analysis. In two trials, clinical effect was assessed in environmental exposure chambers, remaining trials were confirmatory phase III trials conducted as field studies in North America, Europe and Japan. Presented efficacy analyses are based on the primary efficacy endpoint of each trial and investigate a potential difference in efficacy between subjects with pre-treatment specific IgE (kU/L) < _3.5 (Class 2) and >3.5 (Class 3/4/5/6). RESULTS: For the active treatment groups, there was no consistent difference in efficacy outcomes between Class 2 and the combined group of Classes 3/4/5/6. In contrast, there was consistent reduced efficacy for Classes 3/4/5/6 over Class 2 in the placebo groups. An intra-Class group analysis comparing Class 2 active with Class 2 placebo, as well as Class 3/ 4/5/6 active with Class 3/4/5/6 placebo, showed a tendency to a larger treatment effect in subjects with IgE Class >2. CONCLUSIONS: For all SLIT-tablet trials included in this analysis we found a tendency of an increased treatment effect vs placebo for subjects with IgE Classes 3/4/5/6, primarily driven by increased symptom and medication scores during the assessment period of Class 3/4/5/6 subjects compared with Class 2 subjects in the placebo group.
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